Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Shares Outstanding (Weighted Average) (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $86.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 10.05% to $86.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.6 million through Dec 2025, up 10.05% year-over-year, with the annual reading at $86.6 million for FY2025, 10.05% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $86.6 million at Century Therapeutics, roughly flat from $86.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $86.6 million in Q4 2025, with the low at $57.1 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $69.3 million, with a median of $60.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 43.35% in 2024, then grew 1.9% in 2025.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $57.8 million in 2022, then grew by 2.7% to $59.3 million in 2023, then skyrocketed by 32.6% to $78.6 million in 2024, then rose by 10.05% to $86.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $86.6 million, $86.3 million, and $86.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.